Abstract
A live attenuated mumps vaccine (Jeryl-Lynn strain) was evaluated in a field trial which included more than 2300 children who had no previous history of mumps. The objectives were to study antigenic potency and side effects of the vaccine. Parents of vaccinees recorded daily temperatures and other symptoms on a card which was returned. Paired serum specimens were obtained at the time of vaccination and one month later from 1202 children. The results to date indicate: 1. 45 % of 592 children who had no history of having mumps had detectable serum antibody before vaccination; 2. 98% of 340 seronegative vaccinees had 4-fold or greater antibody response; 3. the vaccination was tolerated very well; the incidence of febrile responses and of clinical symptoms was essentially the same in 335 successfully vaccinated children as compared with 252 children who were immune prior to vaccination. These studies indicate that the vaccine is antigenically potent and is clinically acceptable. (SPR)
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brunell, P., Brickman, A. & Krugman, S. 35 Evaluation of a Live Attenuated Mumps Vaccine. Pediatr Res 1, 209 (1967). https://doi.org/10.1203/00006450-196705000-00042
Issue Date:
DOI: https://doi.org/10.1203/00006450-196705000-00042